A new scientific review has found little evidence to support the use of psychedelics, including LSD and psilocybin, for treating attention deficit hyperactivity disorder (ADHD). Despite growing public interest and anecdotal claims, researchers say the current data do not justify clinical use.
Microdosing Lacks Proof
The practice of microdosing—taking sub-perceptual doses of psychedelics—has gained popularity as a potential cognitive enhancer. However, a review of existing studies published in the journal Psychopharmacology concludes that there is no robust scientific backing for its efficacy in ADHD. The analysis examined clinical trials and observational studies on low-dose LSD and psilocybin, finding no significant improvements in attention, focus, or executive function compared to placebo.
Risks Outweigh Benefits
According to Dr. Emily Carter, lead author of the review from the University of Cambridge, “The enthusiasm for psychedelics has outpaced the science. Our review shows that the potential harms, including cardiovascular strain and psychological distress, currently outweigh any unproven benefits for ADHD.” The researchers noted that most studies were small, lacked control groups, or relied on self-reported outcomes.
Growing Interest Despite Gaps
Surveys indicate that up to 25% of adults with ADHD have tried microdosing, often without medical supervision. This trend has spurred calls for more rigorous research, but experts caution against self-medication. “We need large, placebo-controlled trials before any recommendations can be made,” added Dr. Carter. The review also highlighted that psychedelics can interact with common ADHD medications like stimulants, increasing the risk of adverse effects.
Regulatory and Safety Concerns
Psychedelics remain illegal in most countries, and their unregulated use poses legal and health risks. The review urges healthcare providers to discuss these dangers with patients who inquire about alternative treatments. Meanwhile, ongoing studies are exploring psychedelic-assisted therapy for depression and PTSD, but ADHD remains an under-researched area.
